51631-50-6

Basic information

• Product Name: Isopropyl(4-chlorophenyl)acetyl chloride
• Synonyms: 3-methyl-2-(4-chlorophenyl)butyryl chloride;2-(4-Chlorophenyl)-3-methylbutanoyl chloride;2-(4-Chlorophenyl)isovaleryl chloride;isopropyl(4-chlorophenyl)acetyl chloride;2-(4-CHLOROPHENYL)-3-METHYLBUTYRYL;Alpha-Isopropyl-4-Chlorophenyl Acetyl Chloride;2-(4-CHLOROPHENYL)-3-METHYLBUTYL CHLORID;4-chloro-1-(1-methylethyl)benzeneacetyl chloride
• CAS NO: 51631-50-6
• Molecular Formula: C₁₁H₁₂Cl₂O
• Molecular Weight: 231.11838
• Product Categories: Acid Halides;Carbonyl Compounds;Organic Building Blocks;Acid Halides;Building Blocks;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 51631-50-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 124-130°C (3 Torr)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.171 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00205mmHg at 25°C
• Refractive Index: n20/D 1.526(lit.)
• CAS DataBase Reference: Isopropyl(4-chlorophenyl)acetyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: Isopropyl(4-chlorophenyl)acetyl chloride(51631-50-6)
• EPA Substance Registry System: Isopropyl(4-chlorophenyl)acetyl chloride(51631-50-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 51631-50-6(Hazardous Substances Data)

Usage

General Description

Isopropyl(4-chlorophenyl)acetyl chloride is a chemical compound that is derived from isopropyl alcohol and 4-chlorophenylacetyl chloride. It is a colorless liquid with a strong, pungent odor. Isopropyl(4-chlorophenyl)acetyl chloride is commonly used as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds. It is also used in the synthesis of various drugs, including muscle relaxants and anesthetics. Isopropyl(4-chlorophenyl)acetyl chloride is known for its ability to react vigorously with water and alcohols, so it must be handled with care and stored in a cool, dry place.

InChI:InChI=1/C11H12Cl2O/c1-7(2)10(11(13)14)8-3-5-9(12)6-4-8/h3-7,10H,1-2H3

Upstream product

• 140-53-4 p-chlorobenzyl cyanide 
• 622-95-7 4-chlorobenzyl bromide 
• 2012-81-9 3-Methyl-2-(4'-chlorophenyl)-butyronitrile 
• 106-43-4 para-chlorotoluene 
• 2012-74-0 2-(4-chlorophenyl)-3-methylbutyric acid 

Downstream Products

• 131691-17-3 6-chlorocoumarin-4-yl α-isopropyl-4-chlorophenylacetate 
• 67614-32-8 (R)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate 
• 66230-04-4 esfenvalerate 
• 51630-58-1 FENVALERATE 
• 75462-47-4 1-(3-phenoxyphenyl)-2-butyn-1-yl 2-(4-chlorophenyl)-3-methylbutanoate 
• 1001428-92-7 (2RS,1'S,2'S,3'R)-2-(4-chlorophenyl)-N-[2,3-dihydroxy-1-(hydroxymethyl)heptadecyl]-3-methylbutyramide 
• 1224868-15-8 C₁₄H₁₇ClN₂O 
• 51629-80-2 2-(4-Chloro-phenyl)-3-methyl-butyric acid 4-prop-2-ynyl-benzyl ester 
• 1246815-00-8 fenvalerate-¹³C₆D₅ 
• 1390617-10-3 C₁₉H₂₁ClO₄S 
• 1239150-51-6 3-(4-chlorophenyl)-1-hydroxy-4-methylpentan-2-one 
• 2012-74-0 2-(4-chlorophenyl)-3-methylbutyric acid 
• 92742-11-5 p-chlorophenyl isopropyl ketene 

Relevant articles and documents

Synthesis and characterization of chrysanthemic acid esters

A short and convenient synthesis for a series of novel chrysanthemic acid esters from aldehyde and chrysanthemic acid is reported.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

Process for producing an optically active α-isopropyl-p-chlorophenylacetic acid

A process for producing an optically active α-isopropyl-p-chlorophenylacetic acid (ICPA) of the formula: STR1 wherein the symbol * stands for an asymmetric carbon atom.